Compare Repligen Corporation Common Stock (RGEN) vs Weibo Corp (WB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Repligen Corporation Common Stock vs Weibo Corp — how do they compare? Repligen Corporation Common Stock trades at $178.15 (market cap $11.14B), while Weibo Corp trades at $6.43 (market cap $1.61B). The key difference: Repligen Corporation Common Stock is far larger — about 6.9× Weibo Corp's market cap, and Weibo Corp pays a 9.3% dividend while Repligen Corporation Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Repligen Corporation Common Stock for 0 Days and Weibo Corp for 103 Days on average.
| RGEN | WB | |
|---|---|---|
Market Cap | $11.14B | $1.61B |
Volume | 1,259,263 | 585,008 |
Sector | Health | Media |
52-Week High | $194.57 | $11.52 |
52-Week Low | $102.87 | $6.33 |
Typical Hold Time | 0 Days | 103 Days |
Enterprise Value | $11.02B | $841.53M |
Dividend Yield | — | 9.3% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RGEN trades at $175.42, up 1.66% today, with a neutral technical signal and key support at $173. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results due October 27. Revenue grew to $738.26M in 2025, though net income margin is modest at 5.29%. The company recently completed the acquisition of BioLife Solutions, signaling strategic expansion.
Outlook remains positive with strong analyst support (91.67% buy ratings) and a consensus price target of $173.86, though high valuation multiples (P/E 240.34) pose a risk. Earnings growth and integration of acquisitions are key catalysts, but investors face execution risks and market volatility.
Weibo (WB) trades at $6.51, down 0.53% with bearish technical signals despite attractive valuation metrics including a P/E of 5.42 and P/B of 0.4. The company reported Q2 2026 EPS of $0.38, beating expectations, but faces declining user metrics and advertising revenue challenges. Cash flow trends show volatility with a significant net outflow in 2024 followed by recovery in 2025.
WB presents as a deep-value opportunity with strong profitability margins but faces growth headwinds from user engagement declines and competitive pressures. Analyst sentiment is mixed with 41% buy ratings versus 45% hold, reflecting uncertainty about the company's ability to maintain relevance in China's social media landscape.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Repligen Corporation Common Stock
Repligen Corporation develops and manufactures bioprocessing tools and technologies used in biologic drug manufacturing, including filtration and perfusion systems, chromatography columns and resins, and process analytics instruments. Its products support upstream and downstream production workflows for modalities such as monoclonal antibodies, mRNA, and viral vectors.
Read more on RGEN →About Weibo Corp
Weibo is the largest social media platform in China. As of 2020, Weibo had 521 million monthly active users and 225 million daily active users, many of whom are drawn there by the millions of key opinion leaders in entertainment, sports, and business circles. Sina is the major shareholder, holding 44.7% of shares and with 70.8% voting power.
Read more on WB →
